{"title":"在患有慢性肾脏病的 T2DM 患者中,semaglutide 可在 3 年内减少重大肾脏病事件的发生。","authors":"David Collister, Neesh Pannu","doi":"10.7326/ANNALS-24-01579-JC","DOIUrl":null,"url":null,"abstract":"<p><strong>Source citation: </strong>Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. <b>Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.</b> N Engl J Med. 2024;391:109-121. 38785209.</p>","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":null,"pages":null},"PeriodicalIF":19.6000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.\",\"authors\":\"David Collister, Neesh Pannu\",\"doi\":\"10.7326/ANNALS-24-01579-JC\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Source citation: </strong>Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. <b>Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes.</b> N Engl J Med. 2024;391:109-121. 38785209.</p>\",\"PeriodicalId\":7932,\"journal\":{\"name\":\"Annals of Internal Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":19.6000,\"publicationDate\":\"2024-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Internal Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.7326/ANNALS-24-01579-JC\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7326/ANNALS-24-01579-JC","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
Source citation: Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109-121. 38785209.
期刊介绍:
Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine’s mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.